3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Squamous Cell Carcinoma of Head and Neck
30
Oropharyngeal Neoplasms
21
Nasopharyngeal Carcinoma
15
Head and Neck Neoplasms
13
Prostatic Neoplasms
11
Laryngeal Neoplasms
9
Carcinoma, Non-Small-Cell Lung
9
Carcinoma, Squamous Cell
8
Carcinoma
8
Breast Neoplasms
8
Rectal Neoplasms
7
Mouth Neoplasms
7
Hypopharyngeal Neoplasms
7
Glioma
6
Glioblastoma
6
Uterine Cervical Neoplasms
5
Papillomavirus Infections
5
Esophageal Neoplasms
5
Urinary Bladder Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Nasopharyngeal Neoplasms
4
Astrocytoma
4
Mesothelioma, Malignant
3
Lung Neoplasms
3
Leukemia, Myeloid, Acute
3
Endometrial Neoplasms
3
Brain Neoplasms
3
Tumor Virus Infections
2
Tongue Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Interventions
Cisplatin
6
pembrolizumab
5
Nivolumab
5
palbociclib
4
durvalumab
4
Pemetrexed
4
atezolizumab
3
abemaciclib
3
Fulvestrant
3
Carboplatin
3
Anastrozole
3
130-nm albumin-bound paclitaxel
3
selpercatinib
2
ribociclib
2
relatlimab
2
entrectinib
2
cobimetinib
2
capmatinib
2
alectinib
2
Vemurafenib
2
Radiosurgery
2
Paclitaxel
2
Letrozole
2
Gonadotropin-Releasing Hormone
2
Gemcitabine
2
Bevacizumab
2
AZD9833
2
trametinib
1
taletrectinib
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
Radiotherapy, Intensity-Modulated
×
1 year
×
Clear all
NCT04124198
2025-12-31
QoLATI
Rigshospitalet, Denmark
Phase NA
Active not recruiting
138 enrolled